Guggenheim Downgrades Tenax Therapeutics to Neutral After LEVEL Data at ESC 2026
Tenax’s TNX-103 missed the LEVEL primary endpoint. Guggenheim cites encouraging subgroup data in sicker patients but says more work and longer studies may be needed.
/ 3 items
#TENX↓
Tenax’s TNX-103 Misses Primary Endpoint in Late-Stage Heart Failure Trial
Tenax’s heart drug trial missed its main goal, but showed promise in sicker patients, sending shares down more than 85%.
Tenax Therapeutics: Cantor Sees 2x–3x Upside as First PH-HFpEF Drug Nears Pivotal Data
Cantor Fitzgerald initiates Overweight on Tenax Therapeutics with $35 target. Under-the-radar biotech nears Q3 2026 Phase 3 readout for potential first PH-HFpEF therapy — high-risk, high-reward setup.